Abstract:As a means of communication between immune cells and non-immune cells, Interleukins (ILs) has the main functions of stimulating the proliferation and activation of inflammatory immune cells such as dendritic cells and lymphocytes, promote the development of blood cells and so on. However, dysregulation of ILs expression is a major feature of autoinflammatory diseases. The drugs targeting ILs or IL-like biologics have played an important role in the clinical treatment of autoinflammatory diseases. Nevertheless, the widespread use of IL products may result in significant off-target adverse reactions. Thus, there is a clear need to develop next-generation ILs products in the biomedical field. Fusion proteins are proteins created through the joining of two or more genes that originally coded for separate proteins. Over the last 30 years, there has been increasing interest in the use of fusion protein technology for developing anti-inflammatory drugs. In comparison to single-target drugs, fusion proteins, as multiple targets drugs, have the ability to enhance the cytokine therapeutic index, resulting in improved efficacy over classical drugs. The strategy of preparing ILs or their receptors as fusion proteins is increasingly used in the treatment of autoimmune and chronic inflammation. This review focuses on the efficacy of several fusion protein drugs developed with ILs or their receptors in the treatment of autoinflammatory diseases, in order to illustrate the prospects of this new technology as an anti-inflammatory drug development protocol in the future.

[Biologics for Targeting Inflammatory Cytokines and Their Clinical Application].

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

Recent Progress in Capturing and Neutralizing Inflammatory Cytokines

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Therapeutic Antibodies That Target Inflammatory Cytokines in Autoimmune Diseases.

Biologics targeted at TNF: design, production and challenges.

Therapeutic Potential of TNFα Inhibitors in Chronic Inflammatory Disorders: Past and Future

Targeted delivery systems for biological therapies of inflammatory diseases

Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy

Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing

Biological drug and drug delivery-mediated immunotherapy

Therapy Development of B iological Agents in Inflammatory Arthritis

Successful Treatment of Animal Models of Acute Graft-Versus-Host Disease with Small-Molecule TNF Inhibitor

Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

STATs, promising targets for the treatment of autoimmune and inflammatory diseases

Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress

Emerging principles of cytokine pharmacology and therapeutics

Research progress on tumor necrosis factor inhibitors

Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer

Next-generation Cytokines for Cancer Immunotherapy.